Literature DB >> 15929184

Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression.

Dan Xie1, Jonathan-S-T Sham, Wei-Fen Zeng, Li-Hong Che, Meng Zhang, Hui-Xi Wu, Han-Liang Lin, Jian-Ming Wen, Sze-Hang Lau, Liang Hu, Xin-Yuan Guan.   

Abstract

AIM: To investigate the expression pattern of clusterin in colorectal adenoma-carcinoma-metastasis series, and to explore the potential role of clusterin in multistage colorectal tumorigenesis and progression.
METHODS: A colorectal carcinoma (CRC)-tissue microarray (TMA), which contained 85 advanced CRCs including 43 cases of Dukes B, 21 of Dukes C and 21 of Dukes D tumors, were used for assessing the expression of clusterin (clone 41D) and tumor cell apoptotic index (AI) by immunohistochemistry and TUNEL assay, respectively. Moreover the potential correlation of clusterin expression with the patient's clinical-pathological features were also examined.
RESULTS: The positive staining of clusterin in different colorectal tissues was primarily a cytoplasmic pattern. Cytoplasmic overexpression of clusterin was detected in none of the normal colorectal mucosa, 17% of the adenomas, 46% of the primary CRCs, and 57% of the CRC metastatic lesions. In addition, a significant positive correlation between overexpression of clusterin and advanced clinical (Dukes) stage was observed (P<0.01). Overexpression of cytoplasmic clusterin in CRCs was inversely correlated with tumor apoptotic index (P<0.01), indicating the anti-apoptotic function of cytoplasmic clusterin in CRCs.
CONCLUSION: These data suggests that overexpression of cytoplasmic clusterin might be involved in the tumorigenesis and/or progression of CRCs. The anti-apoptotic function of cytoplasmic clusterin may be responsible, at least in part, for the development and biologically aggressive behavior of CRC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929184      PMCID: PMC4316065          DOI: 10.3748/wjg.v11.i21.3285

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Overexpression of clusterin in human breast carcinoma.

Authors:  M Redondo; E Villar; J Torres-Muñoz; T Tellez; M Morell; C K Petito
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Synthesis and functional analyses of nuclear clusterin, a cell death protein.

Authors:  Konstantin S Leskov; Dmitry Y Klokov; Jing Li; Timothy J Kinsella; David A Boothman
Journal:  J Biol Chem       Date:  2003-01-24       Impact factor: 5.157

3.  Cancer incidence trends in urban shanghai, 1972-1994: an update.

Authors:  F Jin; S S Devesa; W H Chow; W Zheng; B T Ji; J F Fraumeni; Y T Gao
Journal:  Int J Cancer       Date:  1999-11-12       Impact factor: 7.396

4.  Clusterin protein diversity in the primate eye.

Authors:  P Wong; B A Pfeffer; S L Bernstein; M L Chambers; G J Chader; Z F Zakeri; Y Q Wu; M R Wilson; S P Becerra
Journal:  Mol Vis       Date:  2000-10-27       Impact factor: 2.367

Review 5.  Clusterin/apolipoprotein J in human aging and cancer.

Authors:  Ioannis P Trougakos; Efstathios S Gonos
Journal:  Int J Biochem Cell Biol       Date:  2002-11       Impact factor: 5.085

6.  Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray.

Authors:  Dan Xie; Jonathan S T Sham; Wei-Fen Zeng; Han-Liang Lin; Li-Hong Che; Hui-Xi Wu; Jian-Ming Wen; Yan Fang; Liang Hu; Xin-Yuan Guan
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

7.  Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate.

Authors:  J Lakins; S A Bennett; J H Chen; J M Arnold; C Morrissey; P Wong; J O'Sullivan; M Tenniswood
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

8.  Apolipoprotein J expression at fluid-tissue interfaces: potential role in barrier cytoprotection.

Authors:  B J Aronow; S D Lund; T L Brown; J A Harmony; D P Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

9.  Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer.

Authors:  J Steinberg; R Oyasu; S Lang; S Sintich; A Rademaker; C Lee; J M Kozlowski; J A Sensibar
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

10.  Role of clusterin in cell adhesion during early phases of programmed cell death in P19 embryonic carcinoma cells.

Authors:  M Fratelli; G Galli; M Minto; G M Pasinetti
Journal:  Biochim Biophys Acta       Date:  1996-04-24
View more
  11 in total

1.  Proteomics analysis of pleomorphic adenoma of the human parotid gland.

Authors:  Ahmet Mutlu; Murat Ozturk; Gurler Akpinar; Murat Kasap; Aylin Kanli
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-11       Impact factor: 2.503

Review 2.  Novel translational strategies in colorectal cancer research.

Authors:  Ignacio Gil-Bazo
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 3.  The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases.

Authors:  S Park; K W Mathis; I K Lee
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

4.  Association between clusterin polymorphisms and esophageal squamous cell carcinoma risk in Han Chinese population.

Authors:  Kun Li; Jian Wang; Zhen-Bin Ma; Guang-Hong Guo
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  Serum clusterin as a tumor marker and prognostic factor for patients with esophageal cancer.

Authors:  Wei Guo; Xiao Ma; Christine Xue; Jianfeng Luo; Xiaoli Zhu; Jiaqing Xiang; Bo Lu; Hecheng Li
Journal:  Dis Markers       Date:  2014-12-10       Impact factor: 3.434

6.  eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells.

Authors:  Ji-Yeon Lee; Hyun-Ji Kim; Seung Bae Rho; Seung-Hoon Lee
Journal:  Oncotarget       Date:  2016-04-05

7.  Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis.

Authors:  Tingting Shi; Koji Fujita; Jian Gong; Mai Nakahara; Hisakazu Iwama; Shi Liu; Hirohito Yoneyama; Asahiro Morishita; Takako Nomura; Joji Tani; Kei Takuma; Tomoko Tadokoro; Takashi Himoto; Kyoko Oura; Kunihiko Tsutsui; Hideki Kobara; Tsutomu Masaki
Journal:  Oncol Rep       Date:  2020-05-29       Impact factor: 3.906

8.  Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.

Authors:  Yong Tang; Fenghua Liu; Chunning Zheng; Shaochuan Sun; Yingsheng Jiang
Journal:  J Exp Clin Cancer Res       Date:  2012-09-11

9.  Clusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78.

Authors:  Cun Wang; Kai Jiang; Dongmei Gao; Xiaonan Kang; Chun Sun; Qinle Zhang; Yan Li; Lu Sun; Shu Zhang; Kun Guo; Yinkun Liu
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

10.  Protein Phosphorylation in Serine Residues Correlates with Progression from Precancerous Lesions to Cervical Cancer in Mexican Patients.

Authors:  Juan Ramón Padilla-Mendoza; Arturo Contis-Montes de Oca; Mario Alberto Rodríguez; Mavil López-Casamichana; Jeni Bolaños; Laura Itzel Quintas-Granados; Octavio Daniel Reyes-Hernández; Fabiola Fragozo-Sandoval; Aldo Arturo Reséndiz-Albor; Claudia Vanessa Arellano-Gutiérrez; Israel López-Reyes
Journal:  Biomed Res Int       Date:  2020-04-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.